Wally S, Albalawi Sr A, Al Madshush A, Aljohani M, Alshehri A, Alamrani F
Cureus. 2024; 16(5):e60891.
PMID: 38910635
PMC: 11193104.
DOI: 10.7759/cureus.60891.
Liu F, Miao W, Nan J, Shi Z, Zhang A, Bo Y
World J Surg Oncol. 2024; 22(1):157.
PMID: 38877554
PMC: 11177431.
DOI: 10.1186/s12957-024-03436-z.
Santero M, de Mas J, Rifa B, Clavero I, Rexach I, Bonfill Cosp X
Clin Transl Oncol. 2023; 26(1):85-97.
PMID: 37368198
PMC: 10761528.
DOI: 10.1007/s12094-023-03219-0.
Zhang Z, Ma C, Luo Y
J Gastrointest Oncol. 2023; 14(2):626-635.
PMID: 37201077
PMC: 10186536.
DOI: 10.21037/jgo-23-211.
Wang P, Chen J, Jiang Y, Jia C, Pang J, Wang S
Gastroenterol Res Pract. 2021; 2021:5592525.
PMID: 34122537
PMC: 8166508.
DOI: 10.1155/2021/5592525.
Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival.
Levy S, van Veenendaal L, Korse C, Breekveldt E, Verbeek W, Vriens M
J Clin Med. 2020; 9(8).
PMID: 32756529
PMC: 7464451.
DOI: 10.3390/jcm9082502.
Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors.
Yan S, Liu T, Li Y, Zhu Y, Jiang J, Jiang L
Ann Transl Med. 2019; 7(20):545.
PMID: 31807527
PMC: 6861764.
DOI: 10.21037/atm.2019.09.114.
Molecular prognostic factors in small-intestinal neuroendocrine tumours.
Samsom K, van Veenendaal L, Valk G, Vriens M, Tesselaar M, van den Berg J
Endocr Connect. 2019; 8(7):906-922.
PMID: 31189127
PMC: 6599083.
DOI: 10.1530/EC-19-0206.
Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
Herrera-Martinez A, Gahete M, Sanchez-Sanchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R
Clin Transl Gastroenterol. 2018; 9(10):196.
PMID: 30297816
PMC: 6175927.
DOI: 10.1038/s41424-018-0058-8.
Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context.
Wagner M, Samaha D, Cuervo J, Patel H, Martinez M, ONeil W
Adv Ther. 2018; 35(8):1215-1231.
PMID: 29987525
PMC: 6096971.
DOI: 10.1007/s12325-018-0745-6.
Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.
Petersenn S, Koch C
Rev Endocr Metab Disord. 2018; 18(4):373-378.
PMID: 29480376
DOI: 10.1007/s11154-018-9442-7.
PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment.
Braga T, Santos-Oliveira R
Diseases. 2018; 6(1).
PMID: 29324681
PMC: 5871954.
DOI: 10.3390/diseases6010008.
Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martinez A, Gahete M, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R
Endocrine. 2017; 59(2):426-437.
PMID: 29196939
DOI: 10.1007/s12020-017-1482-3.
Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M, Zhao P, Shi X, Zhao A, Zhang L, Zhou L
BMC Endocr Disord. 2017; 17(1):39.
PMID: 28705205
PMC: 5508659.
DOI: 10.1186/s12902-017-0190-6.
Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
Neychev V, Kebebew E
Int J Surg Oncol. 2017; 2017:6424812.
PMID: 28593056
PMC: 5448049.
DOI: 10.1155/2017/6424812.
Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I, Segura A, Capdevila J, Lopez C, Garcia-Carbonero R, Grande E
BMC Cancer. 2016; 16(1):858.
PMID: 27821081
PMC: 5100262.
DOI: 10.1186/s12885-016-2901-1.
Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.
Fotouhi O, Kjellin H, Larsson C, Hashemi J, Barriuso J, Juhlin C
J Clin Endocrinol Metab. 2016; 101(10):3616-3627.
PMID: 27459532
PMC: 5052342.
DOI: 10.1210/jc.2016-2028.
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).
Alonso-Gordoa T, Diez J, Molina J, Reguera P, Martinez-Saez O, Grande E
Rare Cancers Ther. 2016; 3:13-33.
PMID: 27182476
PMC: 4837935.
DOI: 10.1007/s40487-015-0007-6.
Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study.
Kos-Kudla B
Contemp Oncol (Pozn). 2016; 19(5):345-9.
PMID: 26793016
PMC: 4709401.
DOI: 10.5114/wo.2015.56006.
SEOM guidelines 2014: improving quality to increase its usefulness.
Garrido P, Rodriguez C
Clin Transl Oncol. 2014; 16(12):1023-4.
PMID: 25392081
PMC: 4239804.
DOI: 10.1007/s12094-014-1246-y.